The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jan. 17, 2017

Filed:

Mar. 06, 2015
Applicant:

Bristol-myers Squibb & Gilead Sciences, Llc, Foster City, CA (US);

Inventors:

Terrence C. Dahl, Sunnyvale, CA (US);

Munir A. Hussain, Belle Mead, NJ (US);

Robert A. Lipper, Pennington, NJ (US);

Robert L. Jerzewski, Belle Mead, NJ (US);

Mark M. Menning, San Francisco, CA (US);

Reza Oliyai, Burlingame, CA (US);

Taiyin Yang, Monte Sereno, CA (US);

Assignee:
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 31/683 (2006.01); A61K 31/536 (2006.01); A61K 31/513 (2006.01); A61K 9/24 (2006.01); A61K 9/20 (2006.01); A61K 31/522 (2006.01); A61K 31/535 (2006.01); A61K 31/551 (2006.01); A61K 31/675 (2006.01);
U.S. Cl.
CPC ...
A61K 31/683 (2013.01); A61K 9/209 (2013.01); A61K 9/2054 (2013.01); A61K 9/2077 (2013.01); A61K 31/513 (2013.01); A61K 31/522 (2013.01); A61K 31/535 (2013.01); A61K 31/536 (2013.01); A61K 31/551 (2013.01); A61K 31/675 (2013.01);
Abstract

In accordance with this invention a novel pharmaceutical product containing efavirenz, emtricitabine and tenofovir DF are provided as a multicomponent unitary oral dosage form, component 1 comprising tenofovir DF (and, optionally, emtricitabine) and component 2 comprising efavirenz, wherein components 1 and 2 are in a stabilizing configuration. In preferred embodiments component 1 is made by dry granulation.


Find Patent Forward Citations

Loading…